We start Healthcare Unfiltered in 2025 with a bang.

I sit down with Dr. Matt Davids, Director of Clinical Research in the Division of Lymphoma at Dana-Farber Cancer Institute, to unpack the latest breakthroughs in leukemia and chronic lymphocytic leukemia (CLL) from the 2024 ASH annual meeting.

A pioneer in CLL treatment, Dr. Davids recounts the development of venetoclax, a transformative therapy he helped bring to clinical use over a decade ago, setting the stage for discussions on emerging updates. Together, they explore advancements in BTK inhibitors across three distinct classes, the potential of novel targeted therapies, innovative combination regimens, and the shifting paradigms in treating blood cancers, including a nod to the latest clinical trials of high potential.

Check out my books "Toxic Exposure" and "The Cancer journey" available everywhere and don't forget to subscribe, like, and comment on this podcast and others.